Myrthe Dieleman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Myrthe Dieleman has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Rene J. Wubbels
Rotterdam Ophthalmic Institute, Rotterdam, the Netherlands
2 shared publications Bart L. M. Zijlmans
The Rotterdam Eye Hospital, Rotterdam, The Netherlands
1 shared publicationFlora B. de Waard‐Van der Spek
Department of Dermatology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
1 shared publicationJan Jansen
The Rotterdam Eye Hospital, Rotterdam, The Netherlands
1 shared publicationKorine van Dijk
Netherlands Institute for Innovative Ocular Surgery, Rotterdam, the Netherlands
1 shared publicationMarijke Wefers Bettink‐Remeijer
The Rotterdam Eye Hospital, Rotterdam, The Netherlands
1 shared publication
Latest Publications
- 16 March 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (3) , e245-e246
High incidence of adverse reactions to locoregional anaesthesia containing hyaluronidase after uneventful ophthalmic surgery
- 16 March 2012
- Published by Wiley in Acta Ophthalmologica
- Vol. 90 (3) , e245-e246
High incidence of adverse reactions to locoregional anaesthesia containing hyaluronidase after uneventful ophthalmic surgery
- 26 October 2011
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 28 (2) , 98-101
Miotics After Modern Cataract Surgery Are History
Purpose: The aim of this study was to investigate the usefulness of a long-acting miotic (physostigmine) after phacoemulsification in preventing peripheral anterior synechiae (PAS), lens dislocation, and high postoperative intraocular pressure. Methods: This was a prospective randomized controlled trial of 400 patients (400 eyes) scheduled for phacoemulsification. Patients were randomly assigned either to receive a single application of physostigmine ointment directly after phacoemulsification or not. The main outcome measures were the change of intraocular pressure (IOP) before and after surgery, number of extra outpatient clinic visits within 4 weeks postoperatively, verbal rating pain scale (VRS), status of the angle by gonioscopy, and best corrected visual acuity (BCVA). Results: There was no significant difference in IOP and BCVA between both groups. There were more patients who reported a VRS score of more than 3 in the physostigmine group ( P =0.021). PAS or (anterior) lens dislocation was not observed. Conclusion: In eyes without co-morbidity, the routine use of physostigmine ointment has lost its rationale.
- 26 October 2011
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 28 (2) , 98-101
Miotics After Modern Cataract Surgery Are History
Purpose: The aim of this study was to investigate the usefulness of a long-acting miotic (physostigmine) after phacoemulsification in preventing peripheral anterior synechiae (PAS), lens dislocation, and high postoperative intraocular pressure. Methods: This was a prospective randomized controlled trial of 400 patients (400 eyes) scheduled for phacoemulsification. Patients were randomly assigned either to receive a single application of physostigmine ointment directly after phacoemulsification or not. The main outcome measures were the change of intraocular pressure (IOP) before and after surgery, number of extra outpatient clinic visits within 4 weeks postoperatively, verbal rating pain scale (VRS), status of the angle by gonioscopy, and best corrected visual acuity (BCVA). Results: There was no significant difference in IOP and BCVA between both groups. There were more patients who reported a VRS score of more than 3 in the physostigmine group ( P =0.021). PAS or (anterior) lens dislocation was not observed. Conclusion: In eyes without co-morbidity, the routine use of physostigmine ointment has lost its rationale.
- 1 September 2011
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 37 (9) , 1589-1597
Single perioperative subconjunctival steroid depot versus postoperative steroid eyedrops to prevent intraocular inflammation and macular edema after cataract surgery
To compare the efficacy of dexamethasone 0.1% eyedrops after phacoemulsification versus a single perioperative subconjunctival injection of betamethasone acetate 5.7 mg/mL to prevent anterior segment inflammation and macular edema. Rotterdam Eye Hospital, Rotterdam, The Netherlands. Randomized clinical trial. Patients scheduled for cataract surgery were randomly assigned to receive a perioperative subconjunctival injection of betamethasone acetate 5.7 mg/mL (Group 1) or postoperative administration of dexamethasone 0.1% eyedrops (Group 2). Primary outcomes were foveal thickness and macular edema on optical coherence tomography (OCT) and anterior chamber flare by a laser flare meter preoperatively and 4 weeks postoperatively. Secondary outcomes were intraocular pressure, need for additional outpatient clinic visits, phacoemulsification energy, verbal-rating pain scale, and corrected distance visual acuity. The study enrolled 400 patients (400 eyes). Four weeks postoperatively, the mean flare values were significantly higher in Group 1 than in Group 2 (P=.003). The incidence of macular edema on OCT and clinically significant macular edema were not significantly different between groups (P=.685 and P=.386, respectively). No significant difference was observed in any other outcome measure. A single subconjunctival betamethasone acetate injection appears to be a useful alternative to prolonged postoperative administration of dexamethasone eyedrops in controlling intraocular inflammation and development of macular edema after phacoemulsification.
- 1 September 2011
- Published by Wolters Kluwer Health in Journal of Cataract & Refractive Surgery
- Vol. 37 (9) , 1589-1597
Single perioperative subconjunctival steroid depot versus postoperative steroid eyedrops to prevent intraocular inflammation and macular edema after cataract surgery
To compare the efficacy of dexamethasone 0.1% eyedrops after phacoemulsification versus a single perioperative subconjunctival injection of betamethasone acetate 5.7 mg/mL to prevent anterior segment inflammation and macular edema. Rotterdam Eye Hospital, Rotterdam, The Netherlands. Randomized clinical trial. Patients scheduled for cataract surgery were randomly assigned to receive a perioperative subconjunctival injection of betamethasone acetate 5.7 mg/mL (Group 1) or postoperative administration of dexamethasone 0.1% eyedrops (Group 2). Primary outcomes were foveal thickness and macular edema on optical coherence tomography (OCT) and anterior chamber flare by a laser flare meter preoperatively and 4 weeks postoperatively. Secondary outcomes were intraocular pressure, need for additional outpatient clinic visits, phacoemulsification energy, verbal-rating pain scale, and corrected distance visual acuity. The study enrolled 400 patients (400 eyes). Four weeks postoperatively, the mean flare values were significantly higher in Group 1 than in Group 2 (P=.003). The incidence of macular edema on OCT and clinically significant macular edema were not significantly different between groups (P=.685 and P=.386, respectively). No significant difference was observed in any other outcome measure. A single subconjunctival betamethasone acetate injection appears to be a useful alternative to prolonged postoperative administration of dexamethasone eyedrops in controlling intraocular inflammation and development of macular edema after phacoemulsification.